市场调查报告书
商品编码
1525477
全球一次性生物反应器市场评估:按产品类型,分子类型,细胞类型,应用,最终用户,地区,机会,预测(2017-2031)Single-use Bioreactors Market Assessment, By Product, By Type of Molecule, By Cell Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球一次性生物反应器市场规模预计将从2023年的36.5亿美元达到2031年的137.7亿美元,预计2024-2031年期间复合年增长率为18.06%。一次性生物反应器市场是医疗产业的重要组成部分,在医疗市场中占有较大的市场规模。污染风险降低、技术进步、新创公司和中小企业采用率的提高以及相对于传统生物反应器的优势等因素正在推动市场的成长。
生物製程领域的一次性生物反应器市场专门从事用于生物製药和生物技术各种应用的一次性生物反应器系统的设计、生产和部署。这些系统为发酵、蛋白质表现和细胞生长等细胞培养活动提供有效且经济实惠的解决方案,从而减少了对传统不銹钢生物反应器的需求。生物製药公司已使用多功能技术在线应对疫情,增加了快速大规模生产 SARS-CoV-2 病毒疫苗的需求。由于 COVID-19 和快速大规模疫苗生产的需要,一次性系统显示出巨大的需求。这促使了大流行后一次性生物反应器市场的扩大。
2023年8月,Repligen XCell ATF上游富集技术被纳入Sartorius Stedim Biotech Inc.的Biostat STR生物反应器,作为Sartorius Stedim Biotech Inc.和Repligen Corp.推出的整合生物反应器系统的一部分。Biostat STR 中包含完全相容的嵌入式 XCell ATF 硬体/软体模组,可透过整合製程分析技术 (PAT) 提供预先定义的高阶控制方案。对50L至2000L上游浓缩製程的单点控制,透过将XCell控制器硬体和软体整合到Biobrain自动化平台中开发,使客户能够以较小的设备占地面积更好地利用设施空间。
一次性生物反应器比传统生物反应器具有临床优势。
与不銹钢生物反应器 (SSB) 相比,一次性生物反应器 (SUB) 已被证明可显着减少水消耗和设施能源使用。然而,一次性零件的处理会带来废弃物产生和潜在环境影响的问题。一次性生物反应器需要的维护更少,设定时间更短,并且更灵活,可以更轻鬆地自订反应器尺寸和配置。一次性生物反应器在製程开发正在进行且产量较低的研发应用中非常有用。此外,SUB 已被证明在生产多种产品的设施中以及在製程灵活性对于生产和产品需求至关重要的情况下非常有用。
技术进步推动全球一次性生物反应器市场
近年来的重大技术进步增加了一次性生物反应器在生物製药生产中的使用。製造商正在想出新的想法来增强一次性生物反应器的薄膜技术、设计、搅拌马达和感测器系统。这些进步使得一次性生物反应器对于大规模细胞培养开发更加有效和有效率。感测器系统的改进以实现更好的过程监测和控制,以及生物反应器袋材料和设计的改进可以促进细胞生长和生产力等重要进步。
本报告针对全球一次性生物反应器市场进行研究与分析,提供市场规模与预测、区域市场前景、市场动态、竞争格局等。
Global single-use bioreactors market is projected to witness a CAGR of 18.06% during the forecast period 2024-2031, growing from USD 3.65 billion in 2023 to USD 13.77 billion in 2031. The single-use bioreactors market is an important part of the healthcare industry, accounting for a significant market size in the healthcare market. Factors such as reduced risk of contamination, technological advancements, increased adoption among startups and SMEs (small and medium-sized enterprises), and advantages over traditional bioreactors drive the market growth.
The market for single-use bioreactors in bioprocessing sector is dedicated to the design, production, and deployment of single-use bioreactor systems for a range of biopharmaceutical and biotechnology uses. These systems reduce the demand for conventional stainless steel bioreactors by offering effective and affordable solutions for cell culture activities including fermentation, protein expression, and cell growth. Biopharmaceutical firms used versatile technology that brought online response to the pandemic, increasing the requirement for quick mass manufacturing of vaccines against the SARS-CoV-2 virus. Single-use systems witnessed huge demand due to coronavirus and the need for large-scale vaccine manufacturing at a fast pace. This led to the expansion of the single-use bioreactors market post pandemic.
In August 2023, Repligen XCell ATF upstream intensification technology was incorporated into Sartorius Stedim Biotech Inc.'s Biostat STR bioreactor as part of an integrated bioreactor system that was introduced by Sartorius Stedim Biotech Inc. and Repligen Corp. A completely compatible embedded XCell ATF hardware and software module that offers pre-defined advanced control recipes with integrated Process Analytical Technology (PAT) has been included in the Biostat STR. A single point of control for 50 L-2000 L upstream intensification processes, developed by the integration of the XCell Controller hardware and software into the Biobrain automation platform, allowing clients to make greater use of their facility space with a smaller equipment footprint.
Single-use Bioreactors Offer Clinical Advantages Over Traditional Bioreactors
When compared to stainless steel bioreactors (SSBs), single-use bioreactors (SUBs) have been demonstrated to significantly reduce water consumption and facility energy use. Disposing of single-use parts, however, presents issues with waste production and possible environmental effects. Single-use bioreactors require less maintenance, have quick setup periods, and are simpler to customize in terms of reactor size and configuration as they provide greater flexibility. In research and development applications, where process development is continuous, and production quantities are low, single-use bioreactors can be useful. Additionally, SUBs have shown to be significantly more helpful in facilities that produce many products and in situations where process flexibility is crucial in terms of quantities and product needs.
Technological Advancements to Advance the Global Single-use Bioreactors Market
Recent substantial technological improvements have led to an increased utilization of single-use bioreactors in biopharmaceutical production. Manufacturers are coming up with new ideas to enhance single-use bioreactor film technologies, designs, stirring motors, and sensor systems. Single-use bioreactors are more effective and efficient for developing cell cultures on a large scale due to such advancements. Improved sensor systems for better process monitoring, control, and improvements in the materials and designs of bioreactor bags can promote cell growth and productivity, including other significant advancements. The AMBR 250 modular, a novel benchtop small bioreactor system for parallel fermentation or cell culture, was launched by Sartorius Stedim Biotech. This system gives bioprocess scientists access to advanced benchtop bioreactor technology for process research by combining a special single-use bioreactor vessel with a flexible system architecture.
Single-use Bioreactor Systems to Dominate Market
In 2023, the single-use bioreactor systems segment accounts for the highest market share in the global single-use bioreactors market. Systems for single-use bioreactors are frequently used in biopharmaceutical manufacturing procedures when a high product yield is necessary. Single-use bioreactors' adaptability, affordability, and high capacity for mass production would spur consumer demand and propel the industry's rapid expansion. The need for faster discovery and increased production of novel bio-therapeutics, such as vaccines, antibodies, enzymes, and hormones, and a rise in the product quantities that these bioreactors can generate are expected to drive the growth of market. Over the forecast period, the category will rise due to major manufacturers' increased focus on providing small-scale bioreactors.
In June 2024, WuXi Biologics Cayman Inc, a CRDMO, announced that its pharmaceutical manufacturing plant in Hangzhou had installed three sets of 5,000L single-use bioreactors in the second drug substance line. The facility's overall capacity will rise from 8,000L to 23,000L due to the recently installed bioreactors, substantially enhancing the company's manufacturing capabilities for clients throughout the world.
Asia-Pacific is Expected to Grow at the Fastest Pace in the Forecast Period
The single-use bioreactor market in Asia-Pacific is anticipated to grow at a high CAGR due to generic medicine manufacturers and recent biosimilar industry players based in the region. It faces commercial pressure to quickly scale up production utilizing disposable technology at reduced prices. Growing population and changing disease patterns are driving the demand for biopharmaceuticals and vaccines throughout Asia. Local companies have opted for single-use solutions to expedite facility construction and accelerate their services in the market.
In the second half of 2024, Syngene International Ltd, a global contract research, development, and manufacturing organization (CRDMO), will begin clinical and commercial supply of its recently renovated biologics facility (Unit 3) in Bangalore, India, to clients in the United States and Europe. With two production chambers and five 2KL single-use bioreactors each, the machines have a production capacity of 20KL.
Future Market Scenario (2024-2031F)
The biopharmaceutical manufacturing sector is rapidly adopting single-use bioreactors as they are better than traditional systems in numerous ways. Advantages include faster turnaround times between production runs, reduced risk of cross-contamination, and lower capital investment.
Single-use bioreactors are predominantly employed in the manufacturing of biopharmaceuticals. However, their usage extends to other areas such as the food and beverage industry, agriculture, and environmental science sector.
More sustainable practices are being supported by single-use bioreactors such as sustainability, which is increasingly becoming an urgent challenge in biomanufacturing. These practices will reduce waste generation, save energy expenses through reducing water and chemical usage and eliminating cleaning and sterilization requirements.
Continuous technological advancements are expected to enhance the performance and reliability of single-use bioreactors in the future. New technologies that can become part of single-use bioreactors include advanced sensors for real-time monitoring, integration of artificial intelligence (AI), machine learning (ML), 3D printing, and IoT devices.
Key Players Landscape and Outlook
Several medical device companies and biotech companies are flourishing in the single-use bioreactors market by planning and adopting new strategies. They are complying with new strategic initiatives for antimicrobial susceptibility testing devices to increase their market presence. New agreements, contracts, acquisitions mergers, investments, and partnerships are major ways through which they are trying to achieve higher market share.
In August 2023, Repligen XCell ATF upstream intensification technology was incorporated into Sartorius Stedim Biotech Inc's Biostat STR bioreactor as part of an integrated bioreactor system. A completely compatible embedded XCell ATF hardware and software module that offers predefined advanced control recipes with integrated Process Analytical Technology (PAT) is now included in the Biostat STR. A single point of control for 50 L-2000 L upstream intensification processes, developed by the integration of the XCell Controller hardware and software into the Biobrain automation platform, allowing clients to make greater use of their facility space with a smaller equipment footprint.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.